CSIMarket


Pds Biotechnology Corp  (PDSB)
Other Ticker:  
 


 

Pds Biotechnology Corp

PDSB's Financial Statements and Analysis



Pds Biotechnology Corp narrowed first quarter of 2024 net loss per share of $-0.30 compare to net loss per share of $-0.32 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.32 realized in previous quarter.


first quarter of 2024
Earnings Per Share Revenues
$ -0.3 $  0 Mill
$+0.02     Unch.    



Pds Biotechnology's Revenue fell by 0 % in first quarter of 2024 (Mar 31 2024) year on year, to $0 million and declined by sequentially.


Pds Biotechnology is

More on PDSB's Income Statement



Pds Biotechnology in the first quarter of 2024 recorded net loss of $-10.603 million, an increase from net loss of $-9.660 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-10.898 million realized in previous quarter.

More on PDSB's Growth

Pds Biotechnology Inventories
PDSB's Cash flow In the first quarter of 2024 company's net cash flow was $10 million


Pds Biotechnology Corp does not pay out common stock dividend.

In trailing twelve-month period Pds Biotechnology Corp payed $ -0.87 cash per share, on a free-cash flow basis .

Book value grew by 26.26 % sequentially to $1.07 per share.
Tangible Book value grew to $ 1.07 per share from $ 0.85.

Company issued 3.92 million shares or 12.70 % in Mar 31 2024.


More on PDSB's Dividends

 Market Capitalization (Millions) 118
 Shares Outstanding (Millions) 35
 Total Debt (Millions $) 24
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 20




Pds Biotechnology Corp does not pay out common stock dividend.

In trailing twelve-month period Pds Biotechnology Corp had negative $ -0.87 cash flow per share, on a free-cash flow basis .

Book value grew by 26.26 % sequentially to $1.07 per share.
Tangible Book value grew to $ 1.07 per share from $ 0.85.

Company issued 3.92 million shares or 12.70 % in Mar 31 2024.


More on PDSB's Balance Sheets

 Market Capitalization (Millions) 118
 Shares Outstanding (Millions) 35
 Total Debt (Millions $) 24
 Revenue (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 20
   


  News about Pds Biotechnology Corp Earnings

PDS Biotechnology Corp Faces Decline in Corporate Behavior and Financial Performance During First Quarter Earnings Season



As the reporting season for January to March 31, 2024, resumes, various companies within the Major Pharmaceutical Preparations sector have released their respective earnings. Among them, PDS Biotechnology Corp, a pharmaceutical company, reported an operating loss of $-10.097627 million for the most recent fiscal period. This article aims to interpret these financial results and provide an overview of the company's performance, along with its groundbreaking clinical trial results for head and neck cancer treatment.
Financial Performance:
Comparing the operating loss in the first quarter of 2024 to the same period in 2023, it is evident that the loss has increased from $-9.422414 million to $...

PDS Biotechnology Corp Shows Significant Improvement in Operating Deficit in Fourth Quarter of 2023



The recent financial results of PDS Biotechnology Corp, a clinical-stage immunotherapy company specializing in targeted immunotherapies for cancer and infectious diseases, have garnered interest among industry experts. An analysis of the company's fourth-quarter earnings in 2023 reveals a notable reduction in the operating deficit compared to the previous year. This positive trend indicates that PDS Biotechnology is making significant progress in its business strategy and operational efficiency. Moreover, the company's recent announcement of inducement stock options to their new CFO, Lars Boesgaard, further highlights its commitment to attracting and retaining top talent to support future growth.

Reimagined Pds Biotechnology Corp Witnesses Substantial Surge in Working Expenditures During the Closing Financial Period of September 30, 2023

Pds Biotechnology Corp: A Bearish Outlook on the Pharmaceutical Industry
In the ever-evolving world of pharmaceutical preparations, Pds Biotechnology Corp seems to be facing significant challenges as it enters the third quarter of 2023. Despite the positive outlook expressed by the company in its recent financial results announcement, a closer look reveals concerning trends that may raise doubts about Pds Biotech's ability to compete in this highly competitive industry.
First and foremost, Pds Biotechnology Corp reported an operating shortfall of $-10.519686 million for the July to September 2023 financial reporting period. This represents a substantial increase from the operating shortfall of $-7.27...

Deterioration in PDS Biotechnology Corp's Performance Raises Concerns for Future Prospects



The financial results of Pds Biotechnology Corp's second quarter of 2023 have attracted significant attention from researchers in the Major Pharmaceutical Preparations sector. While the operating loss has contracted from the previous year, the absence of any top-line mention raises questions about the company's future prospects. As the management seeks new financial strategies to ensure consistent revenue streams, it remains to be seen how these shortfalls and the upcoming financial reports will impact Pds Biotechnology Corp.
1. Operating Loss Contractions:
Pds Biotechnology Corp reported an operating loss of $-12.696173 million for the second quarter of 2023, an increase from the previous ...

Pds Biotechnology Corp Faces Rising Costs in Q1 2023, Yet Continues to Impress Investors with its Growth Potential

Pds Biotechnology Corp, a rising corporation in the biotechnology industry, has recently faced some challenges during the earnings season of January to March 31, 2023. The shareholders were not expecting any changes in the company during this period, however, they paid close attention to PDSBs' operating shortfall that was at $-9.422414 million in the same period. Despite this setback, Pds Biotechnology Corp has shown great potential in its early stages and has garnered the attention of investors and industry experts.
PDSBs has not yet reported its revenue, but to put its latest conduct into context, it is important to compare it to its corporate achievement through the first quarter of 2022, where the c...


Date modified: 2024-05-16T20:52:55+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com